OkadaSO’BrienJS. Tay-Sachs disease: generalized absence of a β-D-N-acetylhexosaminidase component. Science. 1969;165:698–700.
4.
OkadaSO’BrienJS. Discovery of β-hexosaminidase A deficiency in Tay-Sachs disease. Adv Genet. 2001;44:61–66.
5.
O’BrienJSOkadaSChenAFillerupDL. Tay-Sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N Engl J Med. 1970;283:15–20.
6.
O’BrienJSOkadaSHoMW. Ganglioside storage diseases. Fed Proc. 1971;30:956–969.
KabackMLim-SteeleJDabholkarD. Tay-Sachs disease—carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970-1993. JAMA. 1993;270:2307–2315.
9.
KabackMMDesnickRJ. Tay-Sachs disease: from clinical description to molecular defect. Adv Genet. 2001;44:1–9.
10.
KabackMM. Screening and prevention in Tay-Sachs disease: origins, update, and impact. Adv Genet. 2001;44:253–265.
11.
BrumbackRABodensteinerJB. Dystrophin and Duchenne muscular dystrophy: distinguished neuroscientists review the recent revolutionary discoveries of molecular biology. J Child Neurol. 1989;4:238–239.
12.
O’BrienJSKishimotoY. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J. 1991;5:301–308.
BoroCJMeadBT.
A Century of Teaching and Healing, 1892-1992. The First One Hundred Years of the Creighton University School of Medicine. Omaha, NE: Creighton University School of Medicine; 1991.
15.
OffitPA. The Cutter Incident: How America’s First Polio Vaccine Led to the Growing Vaccine Crisis. New Haven, CN: Yale University Press; 2005.
16.
BouzaCMuñozAAmateJM. Postpolio syndrome: a challenge to the health-care system. Health Policy. 2005;71:97–106.
17.
GonzalezHOlssonTBorgK. Management of postpolio syndrome. Lancet Neurol. 2010;9:634–642.